Shots:

• The P-III (MOMENTUM) study evaluating momelotinib vs danazol in 195 patients with myelofibrosis who were symptomatic & anemic across 21 countries. The company is expected the NDA submission in Q2’22
• The trial met all 1EPs & 2EPs i.e., patients achieved  benefit on symptoms, anemia & splenic size, TSS reduction of >50% (25% vs 9%), transfusion independence (31% vs 20%), SRR >35% (23% vs 3%), rate of Grade 3 or worse AEs (54% & 65%), serious TEAEs were 35% & 40%
• Additionally, mean baseline characteristics for all patients were TSS of 27, Hgb of 8 g/dL & platelet count of 145 x 10 9/L. Momelotinib is a potent, selective & orally bioavailable JAK1/2 & ACVR1/ALK2 inhibitor

Ref: Businesswire | Image: Sierra